- Home
- MANH vs NBIX Comparison
MANH vs NBIX Comparison
Compare MANH & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MANH
- NBIX
- Stock Information
- Founded
- MANH 1990
- NBIX 1992
- Country
- MANH United States
- NBIX United States
- Employees
- MANH N/A
- NBIX N/A
- Industry
- MANH Computer Software: Prepackaged Software
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MANH Technology
- NBIX Health Care
- Exchange
- MANH Nasdaq
- NBIX Nasdaq
- Market Cap
- MANH 13.0B
- NBIX 14.4B
- IPO Year
- MANH 1998
- NBIX 1996
- Fundamental
- Price
- MANH $196.81
- NBIX $136.59
- Analyst Decision
- MANH Buy
- NBIX Strong Buy
- Analyst Count
- MANH 11
- NBIX 17
- Target Price
- MANH $226.70
- NBIX $164.94
- AVG Volume (30 Days)
- MANH 485.1K
- NBIX 888.3K
- Earning Date
- MANH 10-21-2025
- NBIX 10-28-2025
- Dividend Yield
- MANH N/A
- NBIX N/A
- EPS Growth
- MANH 9.17
- NBIX 2.97
- EPS
- MANH 3.58
- NBIX 3.39
- Revenue
- MANH $1,057,690,000.00
- NBIX $2,509,900,000.00
- Revenue This Year
- MANH $5.15
- NBIX $20.79
- Revenue Next Year
- MANH $6.66
- NBIX $14.73
- P/E Ratio
- MANH $55.11
- NBIX $40.29
- Revenue Growth
- MANH 6.13
- NBIX 18.42
- 52 Week Low
- MANH $140.81
- NBIX $84.23
- 52 Week High
- MANH $312.60
- NBIX $154.61
- Technical
- Relative Strength Index (RSI)
- MANH 38.19
- NBIX 47.01
- Support Level
- MANH $196.00
- NBIX $135.96
- Resistance Level
- MANH $209.86
- NBIX $140.53
- Average True Range (ATR)
- MANH 5.13
- NBIX 3.19
- MACD
- MANH -0.87
- NBIX -0.87
- Stochastic Oscillator
- MANH 2.35
- NBIX 11.36
About MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.